Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

<p>Relative change in target lesion size across cobolimab dose ranges (<i>N</i> = 69). Note: <i>N</i> number is defined as the safety population minus 15 patients with target lesion size not available after baseline, including those with no postbaseline tumor assessment...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: Diwakar Davar (15023480) (author)
Autres auteurs: Zeynep Eroglu (19276519) (author), Mohammed Milhem (16527976) (author), Carlos Becerra (22053822) (author), Martin Gutierrez (15360052) (author), Antoni Ribas (14837278) (author), Brian Di Pace (22053016) (author), Tianli Wang (22053019) (author), Hailei Zhang (20634191) (author), Srimoyee Ghosh (22053025) (author), Niranjan Yanamandra (22053022) (author), Theo Borgovan (22053031) (author), Shyam Srivats (22053825) (author), Angela Waszak (22053034) (author), Arindam Dhar (15016280) (author), Patricia LoRusso (15134565) (author)
Publié: 2025
Sujets:
Cancer
Cancer Biology
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase I clinical trials
Immunotherapy
Antibody immunotherapy
Checkpoint blockade
Lung Cancer
Oncogenes & Tumor Suppressors
PD-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires